Interesting how when you're dealing with the Top Minds in the world, how small the world becomes....and Amarantus just keeps popping up...
"The data obtained in this study provide strong evidence that volume distribution from the site of delivery in the brain is unlikely to be an impediment to MANF's clinical progress," said John W. Commissiong, PhD, Chief Scientist at Amarantus. "Volume distribution from the site of delivery appears to have been one of the key shortfalls of previous clinical trials of neurotrophic factors in Parkinson's disease. These results provide a higher degree of certainty that MANF is unlikely to fail in the clinic due to inadequate diffusion volumes."
In studies conducted by Dr. Steven Gill's laboratory at the University of Bristol, MANF and GDNF were injected directly into the striatum of separate groups of rats in order to mimic as closely as possible the treatment setting in humans. Seven days following delivery under best available conditions, MANF's diffusion volume was ~30% greater than GDNF's.
http://carpedmstocks.blogspot.com/2012_11_01_archive.html
CED Advisory Commitee - Medgenesis
Steven Gill, M.D.
Dr. Gill is Professor of Neurosurgery at the University of Bristol, UK. He was the principal investigator on the first clinical trial testing intraputaminal GDNF in Parkinson's patients, and is the most experienced clinical user of GDNF worldwide. In addition, he has been Renishaw's key scientific advisor on the development of the neuro|convect® catheter system.
http://www.medgenesis.com/scientific_advisors.htm
Parkinson's Advisory Commitee - Medgenesis
Howard J. Federoff, M.D., Ph.D.
Dr. Federoff is Executive Dean, Georgetown University School of Medicine as well as Executive Vice President, Georgetown University Medical Center. Dr. Federoff formed and leads the US national consortium "The Parkinson's Disease Gene Therapy Study Group" whose mission is to establish a rigorous basis for moving novel gene therapeutics from preclinical studies to clinical trials.
http://www.medgenesis.com/scientific_advisors.htm
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
"The preclinical state of the disease when one is asymptomatic offers a window of opportunity for potential disease-modifying intervention such as medications," stated Howard Federoff, MD, PhD, Executive Vice President for Health Sciences at Georgetown University Medical Center and Executive Dean of Georgetown's School of Medicine, and one of the inventors of the technology.
http://ir.amarantus.com/company-news/detail/1...rs-disease
Cheers
"The data obtained in this study provide strong evidence that volume distribution from the site of delivery in the brain is unlikely to be an impediment to MANF's clinical progress," said John W. Commissiong, PhD, Chief Scientist at Amarantus. "Volume distribution from the site of delivery appears to have been one of the key shortfalls of previous clinical trials of neurotrophic factors in Parkinson's disease. These results provide a higher degree of certainty that MANF is unlikely to fail in the clinic due to inadequate diffusion volumes."
In studies conducted by Dr. Steven Gill's laboratory at the University of Bristol, MANF and GDNF were injected directly into the striatum of separate groups of rats in order to mimic as closely as possible the treatment setting in humans. Seven days following delivery under best available conditions, MANF's diffusion volume was ~30% greater than GDNF's.
http://carpedmstocks.blogspot.com/2012_11_01_archive.html
CED Advisory Commitee - Medgenesis
Steven Gill, M.D.
Dr. Gill is Professor of Neurosurgery at the University of Bristol, UK. He was the principal investigator on the first clinical trial testing intraputaminal GDNF in Parkinson's patients, and is the most experienced clinical user of GDNF worldwide. In addition, he has been Renishaw's key scientific advisor on the development of the neuro|convect® catheter system.
http://www.medgenesis.com/scientific_advisors.htm
Parkinson's Advisory Commitee - Medgenesis
Howard J. Federoff, M.D., Ph.D.
Dr. Federoff is Executive Dean, Georgetown University School of Medicine as well as Executive Vice President, Georgetown University Medical Center. Dr. Federoff formed and leads the US national consortium "The Parkinson's Disease Gene Therapy Study Group" whose mission is to establish a rigorous basis for moving novel gene therapeutics from preclinical studies to clinical trials.
http://www.medgenesis.com/scientific_advisors.htm
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
"The preclinical state of the disease when one is asymptomatic offers a window of opportunity for potential disease-modifying intervention such as medications," stated Howard Federoff, MD, PhD, Executive Vice President for Health Sciences at Georgetown University Medical Center and Executive Dean of Georgetown's School of Medicine, and one of the inventors of the technology.
http://ir.amarantus.com/company-news/detail/1...rs-disease
Cheers
